Technology | June 08, 2015

GE Healthcare Launches Small Cyclotron and PET Tracer Production Solution

System enables increased access to PET imaging

GE Healthcare, FASTlab 2, FDG Duo, GENtrace cyclotron, PET imaging

FASTlab 2 with FDG Duo cassette image courtesy of GE Healthcare

June 8, 2015 - GE Healthcare announced that it has created a solution to make positron emission tomography (PET) tracers for diagnostic imaging more readily available. At the Society for Nuclear Medicine and Molecular Imaging (SNMMI), GE launched new products for radiopharmaceutical manufacturing, including GENtrace, a small cyclotron, with a smaller footprint that is optimized for ease-of-use; and FASTlab 2, a PET tracer production module with FDG Duo cassettes, to maximize the hot cell capacity.

Tracers for positron emission tomography (PET) imaging procedures play a critical role in medical care today. Yet the logistics of getting tracers onsite at healthcare providers' facilities can sometimes prove difficult for sites outside of radiopharmacies' distribution network, particularly in emerging markets.

The GENtrace cyclotron is the third instrument in GE's family of cyclotrons used to produce the isotope fluorine-18 (F-18), which provides the foundation for PET tracer manufacturing. The device is simple to use due to more automated steps, takes up less space and can be operated by a nuclear medicine technician. With these benefits, facilities in emerging markets and those outside the distribution radius for PET tracers can become autonomous in their F-18 manufacturing.

FASTlab 2 is the newest generation of the FASTlab platform for PET tracer production, which contains an automated cassette-based system and the assurance of reliable, reproducible and consistent quality during each run. Users are able to use two independent FASTlab 2 systems performing multiple runs in the same hot cell, gaining efficiency and saving time. FDG Duo is the new cassette complementing the existing FASTlab cassette portfolio, with integrated reagents allowing users to perform two consecutive fluorodeoxyglucose (FDG) citrate runs without having to open the hot cell door. Together, this allows up to four FDG runs or FDG runs with alternative PET tracers in combinations – maximizing the capacity and versatility of the instrument's hot cell output.

Like all other GE FASTlab cassettes, FDG Duo is a pre-assembled integrated cassette, with Good Manufacturing Process (GMP)-grade reagents included in the cassettes. FASTlab 2 also offers flexibility and range because it allows the use of tracer applications from third-party research partners and can help develop additional innovative tracers thanks to two built-in reactors. FASTlab 2 and FDG Duo cassettes can help customers optimize their PET tracer production and achieve more, providing flexible production capacity and better economics.

Using both the GENtrace cyclotron and FASTlab 2 automated PET tracer production platform as a package called TRACERcenter VIP, out-of-network facilities can provide increased access to PET tracers and benefit from the flexibility of customizing tracers for their specific patient needs.

For more information: www.gehealthcare.com

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Overlay Init